Trial Profile
Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Sotigalimab (Primary)
- Indications CNS cancer; Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions; Pharmacokinetics
- 03 Apr 2024 Planned End Date changed from 31 Mar 2024 to 30 Sep 2024.
- 23 Aug 2023 According to Pyxis Oncology, Inc media release, Apexigen has been acquired by Pyxis Oncology
- 03 Apr 2023 Status changed from recruiting to active, no longer recruiting.